Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

Phase 2

• Conditions: Brain Metastases; Non-small Cell Lung Cancer
• Interventions: Drug: Icotinib

• Registration Number: NCT01688713
• Lead Sponsor: Zhejiang Cancer Hospital

Brief Summary

Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are important approaches to the treatment of brain metastases from NSCLC. Known to us, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC, especially for EGFR mutation patients. However, due to the lower concentration of tyrosine kinase inhibitors (TKIs) in the cerebrospinal fluid and its inevitable emergence of drug resistance, brain metastases will be refractory or resistant to standard-dose EGFR inhibitors. Icotinib is one agent of EGFR-TKIs. The previous studies have shown that the Icotinib conventional dose (125mg, TID) is far from reached its maximum tolerable dose. It is a challenge whether the further dose escalation of Icotinib will enhance its concentration in cerebrospinal fluid and thereby improve its therapeutic effect. Here the investigators examine the therapeutic effect and side-effect of double dose of Icitinib in treating patients with brain metastases from NSCLC who have suffered from the failure of conventional dose treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-08
• Study First Submitted: 2012-08-27
• Status Verified: 2012-09
• Study First Submitted QC: 2012-09-19
• Last Update Submitted: 2012-09-19
• Study First Posted: 2012-09-20
• Last Update Posted: 2012-09-20
• Primary Completion: 2015-02
• Study Completion: 2015-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Histological or cytologic diagnosis of NSCLC
• Patients with disease progression after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
• Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
• ECOG performance status 0-2
• Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS)
• Expected survival of greater than 3 months
• Age: 18-75 years
• The patients with key organs maintenance of basic function: Hemoglobin ≥ 9g/dL, White Blood Cell ≥ 3×109/L, Neutrophil count ≥ 1.5×109/L, platelets ≥ 80×109/L, total bilirubin < 1.5 times of the upper normal values, Alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 of the upper normal values, the serum creatinine < 1.5 times of the upper normal values
• Signed informed consent document on file.

Exclusion Criteria

• Brain metastasis without local treatment before
• Patients without the treatment of Icotinib before or the therapeutic time less than 3 months
• More than 3 extracranial organs have metastatic lesions
• The patient with other type malignant tumors before
• The patient with fertility capacity, but without contraceptive application

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Icotinib,Brain metastases	Icotinib	-

Primary Outcome Measures

Name	Time	Method
Progression-free survival (intracranial lesions)	2 years

Secondary Outcome Measures

Name	Time	Method
Partial response rate of intracranial lesions	2 years
Partial response rate of extracranial lesion	2 years
Overall survival	3 years
Health-related quality of life quality	2 years
number of adverse events such as skin rash,diarrhea ,abnormal liver function and so on	2 years

Trial Locations

Locations (1)

Zhejiang Cancer Hospital; 🇨🇳 Hangzhou, Zhejiang, China